Methods of expressing a neuropeptide in a neuron of a subject are described. Methods of altering a behavior in a subject in need thereof are described. Kits are described. Vectors are described.

The present invention pertains to a medicine, said medicine comprising as an active ingredient a substance which suppresses the expression of at least one molecule selected from the group consisting of TMEM5, VSTM2L, C2CDD4D, VSTM2A, LY6G6C and ADRA2C or inhibits the activity thereof, for preventing and/or treating at least one disease or symptom selected from the group consisting of progressive multiple sclerosis, gastroenteritis, myocardial disorder and sudden death. Also, the present invention pertains to a method for screening a substance, which is capable of preventing and/or treating at least one disease or symptom selected from the group consisting of progressive multiple sclerosis, gastroenteritis, myocardial disorder and sudden death, with the use of the expression or activity of the aforesaid molecule as an index.

[Problem] The objectives of the present invention are to provide a method for making an animal that has been stressed, in particular, chronically stressed, affect or develop a specific disease or symptom, and, through elucidating the process from loading stress to affection or onset of the disease or symptom, to provide a useful tool for research and development of preventing or treating methods of the disease or symptom. [Solution] The present invention relates to a method for producing a disease modeling non-human animal having cerebrovascular inflammation, the disease modeling non-human animal, a method for screening a drug using the disease modeling non-human animal, a method for determining the risk of a disease using the presence of cerebrovascular inflammation as an indicator, and a pharmaceutical for preventing and/or treating progressive multiple sclerosis or the like. The present invention enables developing pharmaceuticals for the above described diseases or the like and performing researches for elucidating their pathogenic mechanisms. The present invention also enables determining the risk of affection or onset of progressive multiple sclerosis or the like and preventing and/or treating progressive multiple sclerosis or the like.

Provided is an aquacultured crustacean having improved umami, uses thereof, and a method for producing the same. The crustacean does not burrow in sand, contain glycine and alanine, and has 2400 mg or more of free amino acids per 100 g of abdominal muscle. The content of glycine is 550 mg or more per 100 g of abdominal muscle, and the content of alanine is 140 mg or more per 100 g of abdominal muscle.

A pharmaceutical composition contains Nkx3.2 and a fragment thereof as an active ingredient. The Nkx3.2 and/or the fragment thereof inhibit(s) retinal degeneration caused by oxidative stress and preserve(s) visual function. In addition, the Nkx3.2 and/or the fragment thereof inhibit(s) cell death due to the oxidative stress of retinal pigment epithelial cells and inhibit(s) choroidal neovascularization and retinal edema. Therefore, a composition containing the Nkx3.2 and/or the fragment thereof as active ingredient(s) can be effectively used for preventing or treating retinal dystrophies or macular degeneration.

Provided is an aquacultured crustacean having improved umami, uses thereof, and a method for producing the same. The crustacean does not burrow in sand, contain glycine and alanine, and has 2400 mg or more of free amino acids per 100 g of abdominal muscle. The content of glycine is 550 mg or more per 100 g of abdominal muscle, and the content of alanine is 140 mg or more per 100 g of abdominal muscle.

Viral vector comprising: a capsid and a packaged nucleic acid, wherein the nucleic acid either augments the miRNA downregulated in a Bleomycin-induced lung fibrosis model or in an AAV-TGFβ1-induced lung fibrosis model, or wherein the nucleic acid inhibits the miRNA up-regulated in a Bleomycin-induced lung fibrosis model or in an AAV-TGFβ1-induced lung fibrosis model.

Methods of expressing a neuropeptide in a neuron of a subject are described. Methods of altering a behavior in a subject in need thereof are described. Kits are described. Vectors are described.

The invention provides a light generating system for arthropod keeping, configured to generate system light, wherein in a first operational mode the light generating system is configured to provide the system light having a spectral power distribution, wherein the spectral power distribution comprises: a first spectral power E.sub.1 in a first wavelength range of 360-780 nm; a second spectral power E.sub.2 in a second wavelength range of 360-400 nm; a third spectral power E.sub.S in a third wavelength range of 400-480 nm; a fourth spectral power E.sub.M in a fourth wavelength range of 480-580 nm; a fifth spectral power E.sub.L in a fifth wavelength range of 580-700 nm; a sixth spectral power E.sub.6 in a sixth wavelength range of 620-700 nm; a seventh spectral power E.sub.7 in a seventh wavelength range of 700-780 nm; and wherein: 1.75≤E.sub.M/E.sub.S≤20; E.sub.2/E.sub.1≤0.005; E.sub.7/E.sub.1≤0.022; and E.sub.L/E.sub.1≤0.3; or 0.3<E.sub.L/E.sub.1≤0.8, and 3.4≤E.sub.6/E.sub.S≤14, and wherein the sixth wavelength range comprises a peak between 650-690 nm.

The present disclosure relates to a method for establishing an oral ulcer animal model with Yin-deficiency and fire-excess syndrome based on sleep deprivation, comprising the following steps of: burning buccal mucosa of a rat with phenol to cause a white injury, and obtaining the oral ulcer animal model after 24-48 h; placing the animal model in a sleep deprivation device for 2-7 days; wherein the device is composed of a mouse box in which a plurality of platforms with a diameter of 4-8 cm are arranged at an interval of 10-20 cm from each other; and water is filled among the platforms, and the platforms are about 0.1-2 cm higher than a water surface. The present disclosure overcomes the defects of single evaluation index, short model duration, and unconformity of etiology and clinic existed in the prior art.